News | September 03, 2008

Myocardial Regeneration by Intracoronary Infusion of Bone Marrow Cells Shows Limited Utility

September 3, 2008 – While a recent study into whether using unselected and selected bone-marrow derived cells can help with regeneration of heart tissue did not lead to significant improvement of LVEF and LV volumes in comparison to control group, there was a trend toward significant improvement of LVEF in patients with severely depressed baseline LVEF receiving either MNC or CD34 CXCR4 bone marrow cells

Michal Tendera, professor and chair of cardiology at the Upper-Silesian Cardiac Center, Silesian School of Medicine, Katowice, Poland, explained the findings of the REGENT study at the European Society of Cardiology 2008 Congress in Munich, Germany this week. It is the second-largest trial using bone marrow-derived cells in patients with acute MI and the first large trial for head-to-head comparison of selected and unselected cells

Intracoronary infusion of unselected and selected bone marrow cells proved to be safe and feasible, he said. The study treated patients with an intracoronary infusion of bone marrow-derived unselected mononuclear cells (MNC) and selected CD34 CXCR4 cells in 200 patients with acute myocardial infarction and reduced LVEF ≤ 40%.
Primary end-point was change of LV ejection fraction (LVEF) and volumes measured by MRI before and six months after the procedure.

In patients receiving both selected and unselected bone marrow cells, LVEF increased significantly in comparison to baseline values by 3 percent. This increase, however, was not significantly higher in comparison to the control group. The changes of left ventricular volumes were also comparable in all groups. Significant increase of LVEF was observed in patients treated with either type of bone marrow cells who had baseline LVEF less than the median. Baseline LVEF was an independent predictor of significant increase of LVEF. At the six-month clinical follow-up, the major cardiovascular event rate was low and no difference was seen between the groups.

Dr. Tendera concluded treatment with intracoronary infusion of BMC did not lead to significant improvement of LVEF and LV volumes in comparison to control group, however there was a trend towards significant improvement of LVEF in patients with severely depressed baseline LVEF receiving either MNC or CD34 CXCR4 bone marrow cells.

For more information: [email protected]

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
New Jersey Researcher Exploring New Stem Cell Therapies for Heart Attacks
News | Stem Cell Therapies| August 04, 2017
In petri dishes in her campus laboratory at New Jersey Institute of Technology, Alice Lee is developing colonies of...
Overlay Init